Anne Thirot‐Bidault
Générale de Santé(FR)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Gastrointestinal Tumor Research and Treatment
Most-Cited Works
- → RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study(2018)176 cited
- → Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)(2020)164 cited
- → Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study(2013)123 cited
- → Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues(2015)119 cited
- → Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort(2017)109 cited
- → Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy(2010)79 cited
- → Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials(2018)42 cited
- → FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study(2014)40 cited
- → Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability(2023)38 cited
- → Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)(2014)36 cited